The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).
 
Charles S. Fuchs
Consulting or Advisory Role - Acceleron Pharma; Amgen; Bayer; Celgene; Genentech/Roche; Gilead Sciences; Lilly; Macrogenics; MedImmune; MedImmune; Merck; Momenta Pharmaceuticals; Pfizer; Pharmacyclics; Sanofi; Takeda; Vertex
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck KGaA; Millennium; Novartis; Roche/Genentech; Sanofi; Symphony Evolution; Taiho Pharmaceutical
 
Salah-Eddin Al-Batran
Consulting or Advisory Role - Celgene; Lilly; Merck; Roche
Speakers' Bureau - Celgene; Lilly; Nordic Bioscience; Roche
Research Funding - Celgene; Hospira; Lilly; Medac; Novartis; Roche Pharma AG; Vifor Pharma
 
Ian Chau
Honoraria - Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; Gilead Sciences; Merck Serono; Sanofi
Research Funding - Merck Serono (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Sanofi
 
David H. Ilson
Consulting or Advisory Role - Amgen; Lilly/ImClone; Roche/Genentech
Speakers' Bureau - Genentech/Roche
Research Funding - Amgen; Bayer; Bristol-Myers Squibb
Travel, Accommodations, Expenses - Amgen; Genentech/Roche
 
Eric Van Cutsem
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst)
 
Kohei Shitara
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Sanofi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bayer (Inst); Chugai Pharma (Inst); Lilly (Inst); Takeda (Inst)
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
David Ferry
Employment - Lilly
Stock and Other Ownership Interests - Lilly (I)
Honoraria - Lilly; Roche; Sanofi
Consulting or Advisory Role - Lilly; Roche; Sanofi
Research Funding - AstraZeneca; Roche; Sanofi
Expert Testimony - Lilly
Travel, Accommodations, Expenses - Roche; Sanofi
 
Michael Emig
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Veerle Vanvoorden
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Yanzhi Hsu
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Lilly
 
Yihuan Xu
Employment - Bristol-Myers Squibb (I); Lilly
Stock and Other Ownership Interests - Bristol-Myers Squibb (I); Lilly
 
Andreas Sashegyi
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Mayukh Das
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Manish A. Shah
Consulting or Advisory Role - Lilly
Research Funding - Genentech (Inst); Sanofi (Inst)